- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00174538
Codeine in Sickle Cell Disease
June 29, 2011 updated by: PriCara, Unit of Ortho-McNeil, Inc.
The Effects of Cytochrome P450 2D6 Genotype on Pain Management With Codeine in Sickle Cell Disease
The objective of this study is to determine if a subject's genetic make-up would affect the treatment response to codeine in subjects with sickle cell disease.
Study Overview
Detailed Description
People with sickle cell disease require oral pain medications to manage an acute pain crisis.
Sometimes these individuals fail to obtain adequate pain relief with the medications prescribed for outpatient use resulting in emergency room visits and hospital admissions.
Subsequently, many patients are admitted to the hospital for pain management for a few days until the pain crisis resolves.
The most common medications prescribed to sickle cell individuals for outpatient use include codeine and hydrocodone containing medications (i.e.
Tylenol #3™, Vicodin™, Lortab™).
These medications must be broken down in the body to make the active pain reliever (morphine or hydromorphone, respectively).
Some individuals may not be able to break down these medications to the active pain reliever; therefore, these individuals will likely continue to experience pain unless they take other pain medications.
We will determine whether genotype estimates the ability of CYP2D6 to break down codeine to the active pain reliever in individuals with sickle cell disease.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age >= 18 years old
- Sickle cell disease (HbSS)
- Hydrocodone- or codeine-containing medications to manage an acute pain crisis in the past
Exclusion Criteria:
- Renal dysfunction, serum creatinine (SCr) > 2.0 mg/dl
- Hepatic dysfunction, AST, ALT or direct bilirubin > 3 x upper limit of normal (ULN)
- Codeine allergy
- Medications shown to induce or inhibit CYP2D6
- Women who are pregnant or breast feeding
- Unable to provide written, informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Plasma morphine and codeine concentrations
|
|
CYP2D6 genotype
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Disease severity
|
|
Hospitalizations and admissions
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Stacy S. Shord, PharmD, University of Illinois at Chicago
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2005
Study Completion
December 1, 2005
Study Registration Dates
First Submitted
September 9, 2005
First Submitted That Met QC Criteria
September 9, 2005
First Posted (Estimate)
September 15, 2005
Study Record Updates
Last Update Posted (Estimate)
June 30, 2011
Last Update Submitted That Met QC Criteria
June 29, 2011
Last Verified
July 1, 2005
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Anemia, Sickle Cell
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Respiratory System Agents
- Antitussive Agents
- Codeine
Other Study ID Numbers
- CR007111
- FEN-EMR-4007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.